Publication, Publications Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
Preclinical, Publications Discovery of ALG-093989, a Highly Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancers
Preclinical, Publications Discovery of ALG-094103, a Liver-Targeted and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Liver Cancer
Publication, Publications Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation
Publication, Publications Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles
Publication, Publications Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
ALG-000184, Publications CAM-E ALG-000184, Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B
Other, Publications siRNA ALG-125755, Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B
Other, Publications siRNA ALG-125755, Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver
Preclinical, Publications Small molecule PD-L1 inhibitor ALG-093702, Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models